Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material (original) (raw)

• Regular Article
• Open access
• Published: 12 June 2001

British Journal of Cancer volume 84, pages 1671–1676 (2001)Cite this article

• 741 Accesses
• 38 Citations
• 3 Altmetric
• Metrics details

This article has been updated

Abstract

An antibody-directed enzyme prodrug therapy (ADEPT) system against CEA-positive tumours is currently in phase I clinical trials. It consists of a prodrug, 4-[N,N-bis(2-iodoethyl) amino] phenoxycarbonyl L -glutamic acid (ZD2767P) and a conjugate of the F(ab’)2anti-CEA antibody A5B7 and the bacterial enzyme carboxypeptidase G2 (CPG2). ZD2767P is converted by antibody-targeted CPG2 into an active bifunctional alkylating drug (ZD2767) at the tumour site. The IC50value of the prodrug against the human colorectal tumour LS174T cell line was 55 ± 9 μM following a 1 h exposure. In contrast, co-incubation of ZD2767P with CPG2 resulted in 229-fold increase in activity. Using a modified comet assay, DNA interstrand cross links (ISC) were detected within 1 h of ZD2767P + CPG2 treatment and were repaired by 24 h. A clear dose–response was seen between the level of ISC, growth inhibition and ZD2767 concentration. Administration of a therapeutic dose of ZD2767P 72 h after the F(ab′)2A5B7 conjugate to mice bearing LS147T xenografts resulted in extensive ISC in the tumour after 1 h; repair was seen at 24 h. Tumour biopsies and peripheral lymphocytes were studied in 5 patients on the ADEPT phase I clinical trial. In 4 patients no ISC were detected. These patients also demonstrated poor localization of conjugate and no tumour response was seen. However a significant level of ISC was detected in one tumour biopsy, which also showed evidence of conjugate localization and clinical response. These studies demonstrate the application of the comet assay in the measurement of ISC in vitro and in clinical material and confirm that activation of ZD2767P results in the formation of DNA crosslinks. © 2001 Cancer Research Campaign http://www.bjcancer.com

Similar content being viewed by others

Article PDF

Change history

• 16 November 2011

This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

References

• Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG and Sherwood RF (1998) A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58: 700–703
  Article Google Scholar
• Blakey DC, Valcaccia BE, East S, Wright AF, Boyle FT, Springer CJ, Burke PJ, Melton RG and Bagshawe KD (1993) Antitumour effects of an antibody-carboxypeptidas G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys 22: 1–8
  Article CAS Google Scholar
• Blakey DC, Burke PJ, Davies DH, Dowell RI, East SJ, Eckersley KP, Fitton JE, McDaid J, Melton RG, Niculescu-Duvaz IA, Pinder PE, Sharma SK, Wright AF and Springer CJ (1996) ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumour regressions in colorectal tumour xenografts. Cancer Res 56: 3287–3292
  CAS Google Scholar
• Eccles SA, Court WJ, Box GA, Dean CJ, Melton RG and Springer CJ (1994) Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res 54: 5171–5177
  CAS Google Scholar
• Fairbairn DW, Olive PL and O’Neill KL (1995) The Comet assay: a comprehensive review. Mutat Res 339: 37–59
  Article CAS Google Scholar
• Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, Souhami RL and Hartley JA (1999) Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 5: 507–512
  CAS Google Scholar
• Melton RG, Boyle JM, Rogers GT, Burke P, Bagshawe KD and Sherwood RF (1993) Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. J Immunol Methods 14: 158(1): 49–56
  Article Google Scholar
• Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O’Malley D and Begent RHJ (2000) Antibody-directed Enzme Prodrug Therapy: Efficacy and Mechanism of Action in Colorectal Carcinoma Clin. Cancer Res 6: 765–772
  CAS Google Scholar
• Sherwood RF (1996) Advanced drug delivery reviews: enzyme prodrug therapy. Advanced Drug Delivery Reviews 22: 269–288
  Article CAS Google Scholar
• Sherwood RF, Melton RG, Alwan SM and Hughes P (1985) Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem 148: 447–453
  Article CAS Google Scholar
• Skehan P, Storeng R, Scudiero D, Monks A, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening. J Natl Cancer Inst 82: 1107–1112
  Article CAS Google Scholar
• Spanswick VJ, Hartely JM, Ward TH and Hartely JA (1998) Measurement of drug induced DNA interstrand crosslinking using the single cell gel electrophoresis (Comet) assay In: eds Methods in Molecular Biology: Cytotoxic Drug Resistance Mechanisms. Brown and Brown, Humana Press
• Springer CJ and Niculescu-Duvaz I (1997) Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv Drug Deliv Rev 26: 151–172
  Article CAS Google Scholar
• Springer CJ, Bagshawe KD, Sharma SK, Searle F, Boden JA, Antoniw P, Burke PJ, Rogers GT, Sherwood RF and Melton RG (1991a) Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer 27: 1361–1366
  Article CAS Google Scholar
• Springer CJ, Antoniw P, Bagshawe KD and Wilman DE (1991b) Comparison of the half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzymes prodrug therapy (ADEPT). Anti-Cancer Drugs Design 6: 467–479
  CAS Google Scholar
• Springer CJ, Dowell R, Burke PJ, Hadley E, Davis DH, Blakey DC, Melton RG and Niculescu-Duvaz I (1995) Optimisation of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for ADEPT. J Med Chem 38: 5051–5065
  Article CAS Google Scholar
• Sunters A, Springer CJ, Bagshawe KD, Souhami RL and Hartley JA (1992) The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid. Biochem Pharmacol 44: 59–64
  Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

1. Department of Oncology, CRC Drug–DNA Interactions Research Group and CRC Targeting and Imaging Group, Royal Free and University College School of Medicine, University College London for the Phase I and II Clinical Trials Committee of the Cancer Research Campaign, UK
   S D Webley, R J Francis, R B Pedley, S K Sharma, R H J Begent, J A Hartley & D Hochhauser

Authors

1. S D Webley
   You can also search for this author inPubMed Google Scholar
2. R J Francis
   You can also search for this author inPubMed Google Scholar
3. R B Pedley
   You can also search for this author inPubMed Google Scholar
4. S K Sharma
   You can also search for this author inPubMed Google Scholar
5. R H J Begent
   You can also search for this author inPubMed Google Scholar
6. J A Hartley
   You can also search for this author inPubMed Google Scholar
7. D Hochhauser
   You can also search for this author inPubMed Google Scholar

Rights and permissions

From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Reprints and permissions

About this article

Cite this article

Webley, S., Francis, R., Pedley, R. et al. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.Br J Cancer 84, 1671–1676 (2001). https://doi.org/10.1054/bjoc.2001.1843

Download citation

• Received: 27 November 2000
• Revised: 19 March 2001
• Accepted: 20 March 2001
• Published: 12 June 2001
• Issue Date: 15 June 2001
• DOI: https://doi.org/10.1054/bjoc.2001.1843

Keywords

This article is cited by